scholarly journals Prevalence and Clinical Associations of Antiphospholipid Antibodies in Systemic Sclerosis: New Data From a French Cross-Sectional Study, Systematic Review, and Meta-Analysis

2018 ◽  
Vol 9 ◽  
Author(s):  
Vincent Sobanski ◽  
Angélique Lemaire-Olivier ◽  
Jonathan Giovannelli ◽  
Luc Dauchet ◽  
Myriam Simon ◽  
...  
Keyword(s):  
Systematic Review ◽  
Systemic Sclerosis ◽  
Antiphospholipid Antibodies ◽  
Meta Analysis ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Clinical Associations

scholarly journals The Increasing Risk of Dementia in Psoriasis: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 73 (3) ◽  
pp. 145-154
Author(s):  
Chayada Chaiyabutr ◽  
Narumol Silpa-archa ◽  
Chanisada Wongpraparut ◽  
Leena Chularojanamontri
Keyword(s):  
Systematic Review ◽  
Cohort Study ◽  
Cognitive Impairment ◽  
Meta Analysis ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Inclusion Criteria ◽  
Cross Sectional ◽  
Increasing Risk ◽  
Symptoms And Signs

Objective: To systemically summarize and meta-analyze the risk of dementia in psoriasis patients. Methods: A systematic review was performed in two databases (EMBASE and MEDLINE). The eligible studies had to be a cohort study or a cross-sectional study that compared either the prevalence or incidence of dementia in patients with psoriasis, versus individuals without psoriasis. Results: Of 791 retrieved articles, seven studies met the inclusion criteria and were included into the meta-analysis. The risk of incident and prevalent dementia were significantly higher in patients with psoriasis, with a pooled risk ratio of 1.16 (95% CI: 1.02-1.33; I2 96%) and 1.36 (95% CI: 1.07-1.72; I2 10%), respectively. Conclusions: This study revealed a slight increase in both the incidence and prevalence of dementia in psoriasis patients. However, dermatologists should carefully observe and periodically screen psoriasis patients for this comorbidity, especially among those who have symptoms and signs of cognitive impairment.

The relationship between pemphigus and systemic lupus erythematosus: a cross-sectional study, systematic review, and meta-analysis

2019 ◽  
Vol 67 (1) ◽  
pp. 116-122
Author(s):  
Khalaf Kridin ◽  
Rimma Laufer-Britva ◽  
Mouhammad Kridin ◽  
Doron Comaneshter ◽  
Erez Batat ◽  
...  
Keyword(s):  
Systematic Review ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Meta Analysis ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
The Relationship

scholarly journals Endodontic Epidemiology: A Systematic Review and Meta-Analysis

2019 ◽  
pp. 1-3
Author(s):  
Maraga Edith ◽  
Keyword(s):  
Systematic Review ◽  
Scientific Literature ◽  
Meta Analysis ◽  
Epidemiological Studies ◽  
Cross Sectional Study ◽  
Treatment Modalities ◽  
Sectional Study ◽  
Cross Sectional ◽  
Review Reports ◽  
Randomised Controlled

Pulpitis is a common occurrence in clinical practice. To date, few systematic reviews have evaluated the epidemiology of various treatment modalities in endodontics. The objective of this study is to analyse the epidemiology of endodontics as presented in various publications. Methodology :Clinical, experimental and review reports were searched in PubMed, Cochrane databases and Google Scholar for scientific literature in November 2019, using the search phrase “endodontic epidemiology” Results : Of the eight potentially relevant publications, six of which were randomised controlled trials, with no statistically significant results, one was a systematic review and the other was a cross-sectional study. Conclusion: Endodontic epidemiological studies are being conducted, however the results are not statistically significant. This does not necessarily mean that the results of such studies obtained cannot be applied clinically.

scholarly journals Decreased choroidal and scleral thicknesses in highly myopic eyes with posterior staphyloma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Un Chul Park ◽  
Eun Kyoung Lee ◽  
Bo Hee Kim ◽  
Baek-Lok Oh
Keyword(s):  
Choroidal Thickness ◽  
Structural Changes ◽  
Meta Analysis ◽  
Cross Sectional Study ◽  
Pathologic Myopia ◽  
Sectional Study ◽  
Cross Sectional ◽  
Swept Source ◽  
Posterior Staphyloma ◽  
Myopic Maculopathy

AbstractIn this cross-sectional study, we investigated choroidal thickness (CT) and scleral thickness (ST) in highly myopic eyes and their associations with ocular factors. Patients underwent widefield swept-source optical coherence tomography (OCT) to measure the CT and ST at the subfovea and 3000 μm superior, inferior, temporal, and nasal to the fovea and macular curvature. A total of 237 eyes (154 patients) were included. At all five measurement points, thinner CTs and STs were associated with longer axial lengths (r = − 0.548 to − 0.357, all P < 0.001) and greater macular curvatures (r = − 0.542 to − 0.305, all P < 0.001). The CT and ST were significantly thinner in eyes with posterior staphyloma than in those without at all measurement points (all P ≤ 0.006) but did not differ between eyes with the wide macular and narrow macular type of staphyloma. Eyes with myopic maculopathy of category ≥ 3 according to the International Meta-Analysis for Pathologic Myopia classification had significantly thinner CTs and STs than those with category ≤ 2 (all P ≤ 0.005). In highly myopic eyes, a decrease in the CT and ST was more pronounced in eyes with more structural changes, such as longer axial length, steeper macular curvature, and the presence of posterior staphyloma.

scholarly journals SAT0330 NEW IMMUNOMODULATORY COMBINATION THERAPIES IN PATIENTS WITH SYSTEMIC SCLEROSIS: A RETROSPECTIVE CROSS-SECTIONAL STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1110.1-1111
Author(s):  
J. Qiao ◽  
S. X. Zhang ◽  
T. T. Zhang ◽  
J. Zhang ◽  
M. T. Qiu ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Side Effects ◽  
Lymphocyte Subsets ◽  
Cross Sectional Study ◽  
Peripheral Lymphocyte ◽  
High Morbidity ◽  
Combination Therapies ◽  
Sectional Study ◽  
Cross Sectional ◽  
Long Term Treatment

Background:Systemic sclerosis (scleroderma, SSc) is a rare complex connective tissue disease associated with high mortality and high morbidity1. Active SSc are typically treated with immunosuppressants, which may create a variety of severe side-effects, especially for long-term treatment2. As the pathogenesis of SSc is still a matter of debate, growing evidences have focused on the immune disorders3. However, the quantitative status of lymphocyte subsets in SSc patients are unclear and effects of immunomodulatory combination therapies (avoiding side-effects of conventional therapy) on the lymphocyte subsets are unknown.Objectives:To investigate the quantitative status of peripheral lymphocyte subpopulations and CD4+T subsets in SSc patients for the exploration of SSc pathogenesis and evaluate the effects of new immunomodulatory combination therapies on those cells.Methods:From July 2014 to December 2019, total 166 patients with SSc and 206 healthy controls (HCs) were enrolled in this study, in which, 79 follow-up patients received immunomodulatory drugs (IMiDs) such as low-dose interleukin-2, rapamycin, metformin, retinoic acid and coenzyme Q10. The absolute numbers of T, B, NK, CD4+T, CD8+T, Th1, Th2, Th17 and Tregs in peripheral blood of these subjects were detected by flow cytometry combined with standard absolute counting beads.Results:Patients with SSc had lower absolute counts of total T, NK, Th2, Th17 and Tregs as compared with those of HCs (P<0.05) (Figure 1). After immunomodulatory combination treatments, there were increases in a various of peripheral lymphocyte subsets such as T, B and CD8+T (P< 0.05). Moreover, the increased level of Tregs was much more dramatical than those of other lymphocyte subsets, resulting in the decrease ratios of Teffs/Tregs such as Th1/Tregs and Th2/Tregs and rebuilding immunologic equilibrium (Figure 2).Conclusion:This cross-sectional study clarified the abnormal status of lymphocyte subsets in SSc patients, suggesting lymphocyte subsets, especially Tregs, might be relevant and play a crucial role in the pathogenesis of SSc, thus providing a potential therapeutic target for SSc patients. Immunomodulatory combination therapies effectively increase the level of Tregs as well as other lymphocytes to some degree and maintain the immunologic equilibrium, which may help for SSc patients’ symptom remission.References:[1]Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390(10103):1685-99. doi: 10.1016/S0140-6736(17)30933-9 [published Online First: 2017/04/18][2]Winthrop KL, Weinblatt ME, Bathon J, et al. Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. Ann Rheum Dis 2020;79(1):88-93. doi: 10.1136/annrheumdis-2019-216151 [published Online First: 2019/10/31][3]Skaug B, Khanna D, Swindell WR, et al. Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Ann Rheum Dis 2019 doi: 10.1136/annrheumdis-2019-215894 [published Online First: 2019/11/27]Acknowledgments :None.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document